Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

JUNE 23, 2022

The European Commission (EC) has approved Novartis’ Tabrecta (capmatinib) as a monotherapy to treat advanced non-small cell lung cancer (NSCLC) in adults. The post EC approves Novartis’ Tabrecta for non-small cell lung cancer appeared first on Pharmaceutical Technology.

Medicine 263

Medicine Clinical Trials Clinical Trials Licensing 263

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

APRIL 19, 2024

JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 21, 2023

Enristomig is under clinical development by Inhibrx and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

DECEMBER 26, 2023

Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

FEBRUARY 8, 2024

INCB-161734 is under clinical development by Incyte and currently in Phase I for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. The company also focuses on investigating TIL therapy for treatment of a range of cancer.

Immune Response 100

Immune Response Production Clinical Trials Clinical Trials 100

Pharmaceutical Technology

DECEMBER 4, 2023

KVA-12123 is under clinical development by Kineta and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,…

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 22, 2023

Dresbuxelimab is under clinical development by Akeso and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 21, 2023

Brentuximab vedotin is under clinical development by Seagen and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

JANUARY 4, 2024

BI-1910 is under clinical development by BioInvent International and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2023

FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

OCTOBER 27, 2023

ABBV-927 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,…

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 22, 2023

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 25, 2023

BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 6, 2023

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 5, 2023

TCR-T Library is under clinical development by Alaunos Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

OCTOBER 26, 2023

EU-101 is under clinical development by Eutilex and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Roots Analysis

MARCH 26, 2024

million fatalities reported in 2020 were observed to be associated with lung cancer, which is believed to be one of the most aggressive forms of carcinoma, globally. Specifically, in 2020, the global prevalence of lung cancer was estimated to be 2.6 Close to 1.8

Marketing 40

Marketing Contract Manufacturing Development Manufacturing 40

Fierce Pharma

SEPTEMBER 22, 2023

Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer.

Clinical Trials 123

Clinical Trials Clinical Trials Trials 123

Medical Xpress

FEBRUARY 15, 2023

Patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes, according to results published in Clinical Cancer Research.

Research 97

Research 97

Pharmaceutical Commerce

FEBRUARY 7, 2024

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.

Trials 52

Trials 52

Drug Discovery World

SEPTEMBER 27, 2023

The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.

Antibody 52

Antibody Drugs Development Research 52

Pharmaceutical Commerce

NOVEMBER 16, 2023

Bristol Myers Squibb’s repotrectinib (Augtyro) approved by FDA to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.

FDA Approval 52

FDA Approval 52

Pharmaceutical Commerce

JANUARY 19, 2024

Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.

52

52

Pharmaceutical Technology

JULY 11, 2023

Iovance Biotherapeutics completes a preliminary analysis after the US' FDA found the trial design acceptable for accelerated approval.

Trials 189

Trials 189

Pharmaceutical Commerce

DECEMBER 11, 2023

Phase III INTerpath-002 trial will evaluate the novel individualized neoantigen therapy V940 (mRNA-4157) with Keytruda (pembrolizumab) as an adjuvant treatment for patients with non-small cell lung cancer.

Trials 52

Trials 52

Pharmaceutical Commerce

FEBRUARY 26, 2024

Bayer's BAY 2927088 is under evaluation to treat unresectable or metastatic non-small cell lung cancer with tumors harboring activating HER2 mutations.

40

40

Pharmaceutical Technology

FEBRUARY 26, 2024

Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.

260

260

Medical Xpress

JANUARY 31, 2023

New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC).

Clinical Trials 74

Clinical Trials Clinical Trials Trials Research 74

Delveinsight

AUGUST 6, 2021

The treatment options for Non-Small Cell Lung Cancer (NSCLC) have been flooded in recent years due to improved methods of molecular profiling and better diagnostic tools. Some rare biomarkers for NSCLC include METex14 skipping alterations, ALK rearrangements, HER-2 mutations, RET rearrangements, and many more.

FDA Approval 97

FDA Approval Marketing Protein Trials 97

Pharmaceutical Technology

OCTOBER 31, 2023

ArriVent Biopharma has received the US FDA's breakthrough therapy designation for furmonertinib to treat non-small cell lung cancer.

264

264

Scienmag

NOVEMBER 7, 2021

Oncotarget published “Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver” which reported that herein, the authors investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no (..)

Gene 86

Gene 86

Drug Discovery World

APRIL 16, 2023

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52